SAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.^® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher.

"I am pleased to welcome Dr. Gallagher to our Board during this pivotal time for the company," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "Carol brings a tremendous amount of biopharmaceutical and leadership experience, and her insights will be significant as we continue to advance our mission to positively impact the lives of people living with cancer."

Dr. Gallagher has over 30 years of strategic, commercial, business development and drug development leadership experience in the life sciences industry. Currently, Dr. Gallagher serves as a venture advisor at New Enterprise Associates (NEA), a global venture capital firm. She has also served as a partner with Frazier Healthcare. Previously, Dr. Gallagher was CEO of Calistoga Pharmaceuticals, where she led the company through its acquisition by Gilead Sciences in 2011. Dr. Gallagher has held leadership roles with Eli Lilly, Amgen, Agouron Pharmaceuticals, Pfizer, Idec Pharmaceutics, CancerVax and Anadys Pharmaceuticals. A veteran board director, Dr. Gallagher currently serves as a board member of PMV Pharma, Atara Biotherapeutics and, until its recent acquisition by Bristol Myers Squibb in August 2022, Turning Point Therapeutics.

Dr. Gallagher attended Vanderbilt University and holds Bachelor of Science and Doctor of Pharmacy degrees from the University of Kentucky. She also serves as a Trustee on the Board of Trustees for the Salk Institute. 

Dr. Gallagher commented, "I am thrilled to join the Mirati Therapeutics board of directors during this transformational time for the company. The company's robust pipeline, coupled with recently approved KRAZATI, offers the potential to meaningfully impact the lives of people living with cancer. I look forward to the opportunity to share my experience and insight at this important time for Mirati.

For more information about the Mirati Board of Directors, click here.

About Mirati Therapeutics, Inc.®

Mirati Therapeutics, Inc. is a commercial stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.

For more information about Mirati, visit us at Mirati.com or follow us on Twitter, LinkedIn and Facebook.

Forward Looking Statements

This press release includes forward-looking statements regarding Mirati's business, financial guidance and the therapeutic and commercial potential of KRAZATI^® (adagrasib), MRTX1719 (MTA-cooperative PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133 (selective KRASG12D inhibitor), Mirati's technologies and Mirati's other products in development. Any statement describing Mirati's goals, expectations, intentions or beliefs, financial or other projections, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines.

Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati's annual report on Form 10-K, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission and available at the SEC's Internet site (www.sec.gov). These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Mirati Contacts
Investor Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.